Did you know?

ChinaBio^® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

Free Report

State of China Life Science 2022

Free Content

Week in Review

In My Opinion

Free Articles

Subscriber Content

Aslan Pharma Raises $12.8 Million in NASDAQ Secondary Offering

publication date: Dec 3, 2019

Singapore's Aslan Pharma raised $12.8 million in a secondary offering of its NASDAQ listed ADSs, placing 5.12 million ADSs at $2.50 each. The price of its shares have been on a 7-day roller coaster, rising 12-fold starting from a low on November 22, when Aslan announced preliminary signs of efficacy in a preclinical study of ASLAN003 for acute myeloid leukemia. The rally was cut in half yesterday when Aslan said it would conduct a secondary offering, without releasing details. Today, after announcing terms for the deal, Aslan trading lower by an additional 47% at $2.73, a market capitalization of just under $20 million. More details....

Stock Symbols: (NSDQ: ASLN; TPEx: 6497)

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Click here to join.